= SDRF-Proteomics: Affinity Proteomics Template
:sectnums:
:toc: left
:doctype: book
//only works on some backends, not HTML
:showcomments:
//use style like Section 1 when referencing within the document.
:xrefstyle: short
:figure-caption: Figure
:pdf-page-size: A4

//GitHub specific settings
ifdef::env-github[]
:tip-caption: :bulb:
:note-caption: :information_source:
:important-caption: :heavy_exclamation_mark:
:caution-caption: :fire:
:warning-caption: :warning:
endif::[]

[[status]]
== Status of this Template

This document provides guidelines for annotating affinity-based proteomics experiments in SDRF-Proteomics format. This template extends the core SDRF-Proteomics specification with affinity proteomics-specific metadata fields.

**Status:** Released

**Version:** 1.0.0 - 2026-01

[[abstract]]
== Abstract

Affinity proteomics encompasses experimental approaches that use affinity-based capture methods to study specific protein subsets or interactions. Unlike mass spectrometry-based proteomics, these methods typically use antibodies, aptamers, or other affinity reagents to detect and quantify proteins. Major platforms include Proximity Extension Assay (PEA/Olink), aptamer-based assays (SomaScan), antibody arrays, and immunoaffinity-MS hybrid approaches.

These experiments have unique characteristics: pre-defined protein panels, detection via sequencing/fluorescence rather than MS, high throughput, relative quantification units (NPX, RFU), and platform-specific considerations. This template defines metadata requirements for annotating affinity proteomics experiments, enabling data integration across platforms.

[[scope]]
== Scope

This template covers:

- Proximity Extension Assays (Olink)
- Aptamer-based protein profiling (SomaScan)
- Antibody/bead arrays (Luminex, MSD)
- Reverse phase protein arrays (RPPA)
- Immunoaffinity enrichment followed by MS detection

IMPORTANT: While affinity proteomics extends SDRF-Proteomics, many of these technologies do not use mass spectrometry. The `technology type` and `assay name` columns are adapted accordingly.

[[technology-type]]
== Technology Type Annotation

For affinity proteomics, the `technology type` column MUST reflect the actual detection technology:

|===
|Platform |Technology Type Value

|Olink PEA
|protein profiling by proximity extension assay

|SomaScan
|protein profiling by aptamer-based assay

|Luminex/MSD
|protein profiling by immunoassay

|RPPA
|protein profiling by reverse phase protein array

|Immunoaffinity-MS
|proteomic profiling by mass spectrometry
|===

[[checklist]]
== Checklist

This section defines the metadata columns required and recommended for affinity proteomics experiments.

=== Required Columns

The following columns are REQUIRED for affinity proteomics experiments in addition to the core SDRF-Proteomics requirements:

|===
|Column Name |Description |Cardinality |Ontology/CV |Example Values

|characteristics[affinity reagent]
|Primary reagent type or platform used for affinity-based capture
|1
|Controlled vocabulary
|Olink proximity extension assay, SOMAscan aptamer panel, antibody array, immunoaffinity beads

|characteristics[affinity method]
|General method category for affinity-based detection
|1
|Controlled vocabulary
|proximity extension assay, aptamer-based assay, immunoaffinity capture, sandwich immunoassay, reverse phase protein array
|===

=== Recommended Columns

The following columns are RECOMMENDED for affinity proteomics experiments:

|===
|Column Name |Description |Cardinality |Ontology/CV |Example Values

|characteristics[target protein class]
|Class or category of proteins being targeted by the panel
|0..*
|Controlled vocabulary or free text
|cytokines, inflammation markers, cardiovascular biomarkers, oncology panel, kinases

|comment[panel name]
|Commercial name or identifier of the protein panel
|0..1
|Free text
|Olink Target 96 Inflammation, SomaScan 7K, Olink Explore 3072, custom panel

|comment[panel composition]
|Number and description of targets in the panel
|0..1
|Free text description
|92 proteins, 7000 protein targets, 48 cytokines

|comment[panel version]
|Version of the panel if applicable
|0..1
|Version identifier
|v3.0, 2023-01, lot ABC123

|comment[detection sensitivity]
|Sensitivity or detection limit of the assay
|0..1
|Concentration with unit
|1 pg/mL, 0.1 pg/mL, LOD 5 pg/mL, femtomolar range

|comment[quantification unit]
|Unit of measurement for quantitative values
|0..1
|Unit identifier
|NPX (Normalized Protein eXpression), RFU (Relative Fluorescence Units), pg/mL, MFI

|comment[sample volume]
|Volume of sample used for the assay
|0..1
|Numeric value with unit
|1 uL, 10 uL, 50 uL, 100 uL

|comment[sample type]
|Type of biological sample material
|0..1
|Controlled vocabulary
|serum, plasma (EDTA), plasma (citrate), CSF, urine, tissue lysate

|comment[dilution factor]
|Sample dilution if applied
|0..1
|Ratio or factor
|1:4, 1:100, undiluted, 10x
|===

[[olink-specific]]
== Olink-Specific Checklist

For Olink Proximity Extension Assay experiments:

=== Required for Olink

|===
|Column Name |Description |Example Values

|comment[olink panel]
|Name of the Olink panel
|Target 96 Inflammation, Target 96 Cardiovascular II, Explore 384 Inflammation

|comment[olink platform]
|Olink instrument/platform version
|Olink Target 96, Olink Explore 384, Olink Explore HT
|===

=== Recommended for Olink

|===
|Column Name |Description |Example Values

|comment[NPX normalization]
|Normalization method applied to NPX values
|plate control normalized, intensity normalized, bridge normalized

|comment[QC warning]
|Quality control warnings if any
|QC pass, below LOD, plate effect warning

|comment[olink lot number]
|Reagent lot number for traceability
|lot_2023_001, B12345
|===

[[somascan-specific]]
== SomaScan-Specific Checklist

For SomaScan aptamer-based experiments:

=== Required for SomaScan

|===
|Column Name |Description |Example Values

|comment[somascan menu]
|SomaScan assay menu version
|SomaScan 1.1K, SomaScan 5K, SomaScan 7K, SomaScan 11K

|comment[somascan platform]
|Platform/instrument version
|SomaScan Assay v4.0, SomaScan Assay v4.1
|===

=== Recommended for SomaScan

|===
|Column Name |Description |Example Values

|comment[normalization method]
|Normalization applied to RFU values
|median normalization, calibrator normalization, hybridization control normalization

|comment[sample matrix]
|Sample matrix type
|serum, plasma EDTA, plasma citrate
|===

[[immunoassay-specific]]
== Immunoassay Array Checklist

For Luminex, MSD, and similar bead/plate-based immunoassays:

|===
|Column Name |Description |Example Values

|comment[assay platform]
|Immunoassay platform used
|Luminex xMAP, MSD MULTI-ARRAY, ELLA, Simoa

|comment[antibody source]
|Source of capture/detection antibodies
|R&D Systems, Bio-Rad, custom antibodies, Millipore

|comment[standard curve]
|Whether standard curve was included
|yes, no, included in kit

|comment[detection method]
|Detection methodology
|fluorescence, electrochemiluminescence, enzyme-linked
|===

[[immunoaffinity-ms]]
== Immunoaffinity-MS Checklist

For experiments combining immunoaffinity capture with mass spectrometry:

These experiments use affinity enrichment followed by MS detection. They should include:

1. Standard MS-related columns from core SDRF-Proteomics
2. Affinity-specific columns for the capture step

|===
|Column Name |Description |Example Values

|characteristics[enrichment method]
|Immunoaffinity enrichment approach
|anti-FLAG IP, anti-HA IP, SISCAPA, immuno-MRM

|comment[capture antibody]
|Antibody used for enrichment
|anti-FLAG M2, anti-GFP nanobody, custom polyclonal

|comment[bead type]
|Type of beads used for capture
|Protein A/G agarose, magnetic beads, NHS-sepharose
|===

[[data-file-formats]]
== Data File Formats

Affinity proteomics platforms produce various output formats:

|===
|Platform |Typical File Format |File Extension

|Olink
|Excel or CSV with NPX values
|.xlsx, .csv

|SomaScan
|ADAT format (proprietary) or CSV
|.adat, .csv

|Luminex
|CSV or xPONENT format
|.csv, .xml

|MSD
|Discovery Workbench format
|.xlsx, .csv

|Immunoaffinity-MS
|Standard MS formats
|.raw, .mzML
|===

For `comment[data file]`, use the actual file name regardless of format.

[[example-sdrf]]
== Example SDRF Files

=== Olink Example

ifndef::env-github[]
++++
<div class="sdrf-example-table">
<table>
<thead>
<tr>
<th class="sample-col">source name</th>
<th class="sample-col">characteristics[organism]</th>
<th class="sample-col">characteristics[disease]</th>
<th class="sample-col">characteristics[affinity method]</th>
<th class="ellipsis-col">...</th>
<th class="data-col">comment[olink panel]</th>
<th class="data-col">comment[quantification unit]</th>
<th class="data-col">comment[data file]</th>
</tr>
</thead>
<tbody>
<tr>
<td class="sample-col">patient_001_plasma</td>
<td class="sample-col">homo sapiens</td>
<td class="sample-col">rheumatoid arthritis</td>
<td class="sample-col">proximity extension assay</td>
<td class="ellipsis-col">...</td>
<td class="data-col">Target 96 Inflammation</td>
<td class="data-col">NPX</td>
<td class="data-col">plate1_results.xlsx</td>
</tr>
<tr>
<td class="sample-col">patient_002_plasma</td>
<td class="sample-col">homo sapiens</td>
<td class="sample-col">normal</td>
<td class="sample-col">proximity extension assay</td>
<td class="ellipsis-col">...</td>
<td class="data-col">Target 96 Inflammation</td>
<td class="data-col">NPX</td>
<td class="data-col">plate1_results.xlsx</td>
</tr>
</tbody>
</table>
<div class="sdrf-legend">
<span class="legend-item"><span class="legend-color sample-bg"></span> Sample metadata</span>
<span class="legend-item"><span class="legend-color data-bg"></span> Data file metadata</span>
</div>
</div>
++++
endif::[]

ifdef::env-github[]
|===
|source name |characteristics[organism] |characteristics[disease] |characteristics[affinity method] |... |comment[olink panel] |comment[quantification unit] |comment[data file]

|patient_001_plasma |homo sapiens |rheumatoid arthritis |proximity extension assay |... |Target 96 Inflammation |NPX |plate1_results.xlsx
|patient_002_plasma |homo sapiens |normal |proximity extension assay |... |Target 96 Inflammation |NPX |plate1_results.xlsx
|===
endif::[]

=== SomaScan Example

ifndef::env-github[]
++++
<div class="sdrf-example-table">
<table>
<thead>
<tr>
<th class="sample-col">source name</th>
<th class="sample-col">characteristics[organism]</th>
<th class="sample-col">characteristics[disease]</th>
<th class="sample-col">characteristics[affinity method]</th>
<th class="ellipsis-col">...</th>
<th class="data-col">comment[somascan menu]</th>
<th class="data-col">comment[quantification unit]</th>
<th class="data-col">comment[data file]</th>
</tr>
</thead>
<tbody>
<tr>
<td class="sample-col">subject_A_serum</td>
<td class="sample-col">homo sapiens</td>
<td class="sample-col">type 2 diabetes mellitus</td>
<td class="sample-col">aptamer-based assay</td>
<td class="ellipsis-col">...</td>
<td class="data-col">SomaScan 7K</td>
<td class="data-col">RFU</td>
<td class="data-col">somascan_batch1.adat</td>
</tr>
</tbody>
</table>
<div class="sdrf-legend">
<span class="legend-item"><span class="legend-color sample-bg"></span> Sample metadata</span>
<span class="legend-item"><span class="legend-color data-bg"></span> Data file metadata</span>
</div>
</div>
++++
endif::[]

ifdef::env-github[]
|===
|source name |characteristics[organism] |characteristics[disease] |characteristics[affinity method] |... |comment[somascan menu] |comment[quantification unit] |comment[data file]

|subject_A_serum |homo sapiens |type 2 diabetes mellitus |aptamer-based assay |... |SomaScan 7K |RFU |somascan_batch1.adat
|===
endif::[]

[[best-practices]]
== Best Practices for Affinity Proteomics Annotation

1. **Specify the platform clearly**: Always identify the specific technology platform used.

2. **Document panel information**: Include panel name, version, and composition for reproducibility.

3. **Report quantification units**: Different platforms use different scales (NPX, RFU, pg/mL) - always specify.

4. **Note sample requirements**: Document sample type, volume, and any dilutions applied.

5. **Include QC information**: When available, note quality control status or warnings.

6. **Use appropriate technology type**: Do not use MS-specific technology types for non-MS platforms.

7. **Link to panel documentation**: When possible, reference manufacturer documentation for panel contents.

8. **Consider cross-platform studies**: When combining affinity and MS data, clearly distinguish samples and methods.

[[cross-platform]]
== Cross-Platform Data Integration

When combining affinity proteomics with mass spectrometry data:

- Use consistent `source name` values for the same biological samples
- Clearly distinguish technology types in the SDRF
- Consider using `characteristics[biosample accession number]` to link related samples
- Document any batch effects or platform-specific normalizations

[[template-file]]
== Template File

The affinity proteomics SDRF template file is available in this directory:

- link:affinity-proteomics-template.sdrf.tsv[affinity-proteomics-template.sdrf.tsv]

[[validation]]
== Validation

Affinity proteomics SDRF files should be validated using the sdrf-pipelines tool:

[source,bash]
----
pip install sdrf-pipelines
parse_sdrf validate-sdrf --sdrf_file your_file.sdrf.tsv --template affinity-proteomics
----

NOTE: Some MS-specific validations may not apply to non-MS affinity platforms.

[[authors]]
== Authors and Maintainers

This template was developed by the SDRF-Proteomics community with contributions from affinity proteomics researchers.

For questions or suggestions, please open an issue on the https://github.com/bigbio/proteomics-metadata-standard[GitHub repository].

[[references]]
== References

- Assarsson E, et al. (2014) Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS ONE.
- Gold L, et al. (2010) Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS ONE.
- Olink Proteomics: https://www.olink.com/
- SomaLogic: https://somalogic.com/
- Schwenk JM, et al. (2017) The Human Protein Atlas as a proteomic resource for biomarker discovery. Journal of Internal Medicine.
